Subscribe to RSS
DOI: 10.1055/s-0030-1255156
© Georg Thieme Verlag KG Stuttgart · New York
Hepatologie 2010
Hepatology 2010Publication History
Publication Date:
09 June 2010 (online)
Was ist neu?
-
Hepatitis B: Aktuelle europäische Therapieempfehlungen.
-
Hepatitis C: Neue antivirale Substanzen in Kombination mit Standardtherapie, IL28B-Polymorphismus als Prognoseparameter.
-
Cholestatische Hepatopathien: Neue Einblicke in die Pathogenese.
-
Leberzirrhose – Komplikationen: Senkung des hepatischen Venenverschlussdrucks durch Carvedilol.
-
Hepatozelluläres Karzinom: Prognoseabschätzung mit MicroRNA.
-
Cholangiozelluläres Karzinom: Standardtherapie mit Gemcitabin und Cisplatin.
Literatur
- 1 EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009; 51 237-267
- 2 Abraldes J G, Albillos A, Banares R. et al . Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009; 136 1651-1658
- 3 Appenrodt B, Grunhage F, Gentemann M G. et al . Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology. 2010; 51 1327-1333
- 4 Ascha M S, Hanouneh I A, Lopez R. et al . The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010 [Epub ahead of print];
- 5 Bajaj J S, Saeian K, Schubert C M. et al . Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology. 2009; 50 1175-1183
- 6 Bass N M, Mullen K D, Sanyal A. et al . Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010; 362 1071-1081
- 7 Chang T T, Lai C l, Kew Yoon S. et al . Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010; 51 422-430
- 8 Cornberg M, Manns M P. Entecavir – Möglichkeiten und Grenzen einer effektiven Therapie der chronischen Hepatitis B. Dtsch Med Wochenschr. 2010; 135 32-37
- 9 European Association for the Study of the L EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009; 50 227-242
- 10 Faivre S, Raymond E, Boucher E. et al . Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 2009; 10 794-800
- 11 Fellay J, Thompson A J, Ge D. et al . ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010; 464 405-408
- 12 Gao M, Nettles R E, Belema M. et al . Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010; 465 96-100
- 13 Ge D, Fellay J, Thompson A J. et al . Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461 399-401
- 14 Germani G, Pleguezuelo M, Gurusamy K. et al . Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol. 2010; 52 380-388
- 15 Gluud L l, Christensen K, Christensen E. et al . Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology. 2010; 51 576-584
- 16 Gramantieri L, Ferracin M, Fornari F. et al . Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 2007; 67 6092-6099
- 17 Hirschfield G M, Liu X, Xu C. et al . Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med. 2009; 360 2544-2555
- 18 Hoofnagle J H. A step forward in therapy for hepatitis C. N Engl J Med. 2009; 360 1899-190
- 19 Jara P, Hierro L, Martinez-Fernandez P. et al . Recurrence of bile salt export pump deficiency after liver transplantation. N Engl J Med. 2009; 361 1359-1367
- 20 Ji J, Shi J, Budhu A. et al . MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009; 361 1437-1447
- 21 Karlsen T H, Franke A, Melum E. et al . Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology. 2010; 138 1102-1111
- 22 Keitel V, Burdelski M, Vojnisek Z. et al . De novo bile salt transporter antibodies as a possible cause of recurrent graft failure after liver transplantation: a novel mechanism of cholestasis. Hepatology. 2009; 50 510-517
- 23 Kircheis G, Knoche A, Hilger N. et al . Hepatic encephalopathy and fitness to drive. Gastroenterology. 2009; 137 1706-1715 e1701 – 1709
- 24 Koeberle D, Montemurro M, Samaras P. et al . Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010; 15 285-292
- 25 Kota J, Chivukula R R, O’donnell K A. et al . Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009; 137 1005-1017
- 26 Lammer J, Malagari K, Vogl T. et al . Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2009; 33 41-52
- 27 Lanford R E, Hildebrandt-Eriksen E S, Petri A. et al . Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010; 327 198-201
- 28 Lange C M, Bojunga J, Hofmann W P. et al . Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology. 2009; 50 2001-2006
- 29 Marcello T, Grakoui A, Barba-Spaeth G. et al . Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006; 131 1887-1898
- 30 Mchutchison J G, Lawitz E J, Shiffman M l. et al . Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009; 361 580-593
- 31 Mchutchison J G, Manns M P, Muir A J. et al . Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010; 362 1292-1303
- 32 Osborne N J, Gurrin L C, Allen K J. et al . HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology. 2010; 51 1311-1318
- 33 Petersen K F, Dufour S, Hariri A. et al . Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010; 362 1082-1089
- 34 Ratziu V, Charlotte F, Bernhardt C. et al . Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology. 2010; 51 445-453
- 35 Rauch A, Kutalik Z, Descombes P. et al . Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010; 138 1338-1345, 1345 e1331 – 1337
- 36 Robek M D, Boyd B S, Chisari F V. Lambda interferon inhibits hepatitis B and C virus replication. J Virol. 2005; 79 3851-3854
- 37 Sanyal A J, Chalasani N, Kowdley K V. et al . Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. N Engl J Med. 2010; 362 1675-1685
- 38 Sarrazin C, Berg T, Ross R S. et al . Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virus-(HBV-)Infektion. Z Gastroenterol. 2010; 48 289-351
- 39 Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010; 138 447-462
- 40 Shim J H, Lee H C, Kim K M. et al . Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010; 52 176-182
- 41 Suppiah V, Moldovan M, Ahlenstiel G. et al . IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41 1100-1104
- 42 Tanaka Y, Nishida N, Sugiyama M. et al . Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41 1105-1109
- 43 Thimme R, Spangenberg H C, Blum H E. Hepatologie 2009. Dtsch Med Wochenschr. 2009; 134 1335-1339
- 44 Thomas D l, Thio C l, Martin M P. et al . Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461 798-801
- 45 Toso C, Merani S, Bigam D l. et al . Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology. 2010; 51 1237-1243
- 46 Tripathi D, Ferguson J W, Kochar N. et al . Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology. 2009; 50 825-833
- 47 Valle J, Wasan H, Palmer D H. et al . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362 1273-128
- 48 Van Bommel F, De Man R A, Wedemeyer H. et al . Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010; 51 73-80
- 49 Viswanathan S R, Powers J T, Einhorn W. et al . Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009; 41 843-848
- 50 Wu I C, Lai C l, Han S H. et al . Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology. 2010; 51 1185-1189
- 51 Xiong Y, Fang J H, Yun J P. et al . Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology. 2010; 51 836-845
- 52 Zhu A X, Sahani D, Duda D G. et al . Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009; 27 3027-3035
Prof. Dr. R. Thimme
Medizinische Universitätsklinik Freiburg
Abteilung
Innere Medizin II
Hugstetter Strasse 55
79106
Freiburg
Phone: 0761/270 3317
Fax: 0761/270 3317
Email: robert.thimme@uniklinik-freiburg.de